Abstract
We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
Original language | English |
---|---|
Pages (from-to) | 1058-1060 |
Number of pages | 3 |
Journal | Pediatric Blood and Cancer |
Volume | 62 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2015 Jun 1 |
Keywords
- Genomic PCR
- MRD
- PDGFRB fusion
- Ph-like ALL
- TKI
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology